Reliability of urinary 6-sulfatoxymelatonin as a biomarker in breast cancer

International Journal of Biological Markers

Volumn 21, Issue 4, 2006, Pages 242-245

  Barba, M ^a,b   Cavalleri, A ^c   Schunemann H J ^a,d,e,f   Krogh, V ^c   Evangelista, A ^c   Secreto, G ^c   Micheli, A ^c   Zhou, Q ^d   Fuhrman, B ^g   Teter, B ^g   Berrino, F ^c   Muti, Paola ^a,h  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY AT BUFFALO   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h NONE   (Italy)

Author keywords

6 Sulfatoxymelatonin; Biomarker; Breast cancer; Cryopreservation; Storage temperature

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; CRYOPRESERVATION; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; PLOTS AND CURVES; POSTMENOPAUSE; PROTEIN DEGRADATION; RELIABILITY; STATISTICAL DISTRIBUTION; STORAGE TEMPERATURE; URINE LEVEL;

EID: 33846469534     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.345     Document Type: Article

References (13)

1. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34: 1-10.
2. Karbownik M, Lewinski A, Reiter RJ. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol 2001; 33: 735-53.
3. Cerutti P, Ghosh R, Oya Y, Amstad P. The role of the cellular antioxidant defense in oxidant carcinogenesis. Environ Health Perspect 1994; 102 (Suppl 10): S123-9.
4. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002; 2: 113-32.
5. Wetterberg L. Melatonin in humans physiological and clinical studies. J Neural Transm Suppl 1978; 13: 289-310.
6. Nowak R, McMillen IC, Redman J, Short RV. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol 1987; 27: 445-52.
7. Lang U, Kornemark M, Aubert ML, Paunier L, Sizonenko PC. Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. J Clin Endocrinol Metab 1981; 53: 645-50.
8. Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985; 60: 1166-73.
9. Cook MR, Graham C, Kavet R, Stevens RG, Davis S, Kheifets L. Morning urinary assessment of nocturnal melatonin secretion in older women. J Pineal Res 2000; 28: 41-7.
10. Baskett JJ, Cockrem JF, Antunovich TA. Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function. J Pineal Res 1998; 24: 58-61.
11. Schernhammer ES, Rosner B, Willett WC, Laden F, Colditz GA, Hankinson SE. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev 2004; 13: 936-43.
12. Platek M, Krogh V, Micheli A, et al. Serum fructosamine and subsequent breast cancer risk: a nested case-control study in the ORDET prospective cohort study. Cancer Epidemiol Biomarkers Prev 2005; 14: 271-4.
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 8: 307-10.